Search Results

Evotec SE has announced the extension of its 20-year collaboration with CHDI Foundation, Inc. CHDI is a privately funded nonprofit biomedical research organisation exclusively dedicated to collaboratively developing therapeutics that will substantially improve the lives of those affected by Huntington’s disease.

SignalChem Biotech provides diverse recombinant Tau proteins for research, helping advance tau-targeted therapies that may modify disease progression in Alzheimer’s and related tauopathies.

Geneoscopy, Inc. will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.

Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored the first large-scale US study of how pneumococcal disease (PD) manifests by age group, insurance status, and sociodemographic characteristics in young children aged 0–2 years during the study period (1998–2019).

MilliporeSigma and The Michael J. Fox Foundation for Parkinson’s Research (MJFF), are advancing research aimed at slowing progression of Parkinson’s disease (PD).

Kannalife Sciences, Inc. is pleased to announce it has been awarded funding of $1,493,409 million from The Michael J. Fox Foundation for Parkinson’s Research.

Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn’s & Colitis Foundation (the “Foundation”) as its sample management services provider for two of its large-scale prospective research cohorts, CAPTURE IBD and IBD SIRQC, which investigate pediatric and surgical care for Crohn’s disease and ulcerative colitis.

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.

Unravel Biosciences, Inc., (“Unravel”), an AI-enabled therapeutics company established to advance drugs for complex diseases, and the Pitt Hopkins Research Foundation (the “Foundation”) today announced a collaboration to conduct a proof of concept clinical trial of vorinostat (RVL-001) in patients with Pitt Hopkins Syndrome (PTHS).